Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.
about
Pharmacology and Clinical Drug Candidates in Redox MedicineExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseFructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review.Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisMeasurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsComorbidities in patients with crystal diseases and hyperuricemia.Global metabolomic profiling of acute myocarditis caused by Trypanosoma cruzi infectionThe pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortalityEndothelial progenitor cells enter the aging arenaHyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studiesUric Acid as a Marker of Mortality and Morbidity in Fabry Disease.Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data.Role of Community Pharmacies for the Detection of Potentially Inappropriate Xanthine Oxidase Inhibitor PrescriptionsRationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis.Xanthine oxidase and cardiovascular risk in obese children.Oxidative stress and early atherosclerosis: novel antioxidant treatment.CVD and Oxidative Stress.Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.Impact of allopurinol on risk of myocardial infarction.The hypoxanthine-xanthine oxidase axis is not involved in the initial phase of clinical transplantation-related ischemia-reperfusion injury.Xanthine oxidase inhibitors in ischaemic heart disease.Baseline and Change in Uric Acid Concentration Over Time Are Associated With Incident Hypertension in Large Korean Cohort.Uric Acid for Cardiovascular Risk: Dr. Jekyll or Mr. Hide?Extracellular but not cytosolic superoxide dismutase protects against oxidant-mediated endothelial dysfunctionFebuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.Acute gouty arthritis complicated with acute ST elevation myocardial infarction is independently associated with short- and long-term adverse non-fatal cardiac events.Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities.Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.Cardiac and renal protective effects of urate-lowering therapy.Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension.Effect of Xanthine Oxidase Inhibition on Arterial Stiffness in Patients With Chronic Heart Failure.A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting.Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery DiseaseInappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry
P2860
Q26785525-F33C7B0A-D5CE-4447-97A0-ECF890034B6AQ26801173-3912360A-B5BE-4697-8373-844D1FD9CCC7Q30234756-7DCFCE55-9429-4CBA-949B-339F8063E2CCQ30248398-7AB1BD51-8F7D-4606-8EE5-1094310FC476Q33838927-0F39A646-CCD6-43A1-BC36-33698205FA3CQ33862472-3A90C614-1592-43EC-B8C6-EE22C128237FQ33864537-C95B6A50-8A61-4689-8D4A-AC1DA2F14D2BQ34157725-3506B418-1BF6-4A75-A1F4-0D9213141845Q34549735-13421C99-52CF-4065-9776-99608506B454Q34877729-3866750D-0C40-4AD7-911A-94C2198FAC0AQ35765879-8DE51A9D-FFE0-4BEC-B50D-E5224B8396C6Q36177428-C5208C97-69F2-41F6-9129-F31A7BD34A96Q36189989-D242F26A-DA31-4EDC-BCF2-D273E699875CQ36317644-EF733FF8-EA2B-4F27-9F16-4394E622AA3CQ36942867-257EE68E-0EA9-4F4C-A9E6-09CCB4221431Q37018125-DCE2AB8B-2030-4347-B5CA-90788BC207F9Q37625569-D191DD2E-08CF-4DE9-8752-EBBA216868B2Q37710722-BC0071B6-694E-4018-B763-2D9B4876EA48Q38269619-C69A8E79-FAFD-47C1-93D1-B3D7030650A4Q38754143-1B6CC17D-6289-4DAF-B98B-26D8B9F9683CQ38968869-073B0E5C-4885-45CB-B21C-FC87EB3A12E0Q39033643-91D1A13D-18F5-4595-8ADA-AE46F2C9FA17Q39057251-85D5453F-4F1A-47A5-8556-2F5E58372FC5Q39324330-B55BE542-E160-45A0-AD30-E66244257CE7Q39456842-2B8A26E7-9CB7-4CFF-B8E2-EF34790FCC9EQ41983713-F3DBC656-034C-491B-B521-84FFCA3FBCA2Q42270598-A01450CB-367B-43BB-B24A-1B739F69F087Q43545502-483F1A87-9FA2-444F-92B8-8274FCCD049FQ43778043-23D23497-5028-4EA6-BA7F-0FA3D05A8175Q46042171-6D648403-C119-41D7-BF13-35E603D88A1FQ48799743-B0757E76-DBC1-46E3-80E7-07047C80FDC2Q49584618-16992E2C-9A3F-4EDD-A935-DCCA057B8A0FQ49616077-BE414148-210D-4C7A-A005-14FECFBF3153Q52668831-CC8EE2F3-C02D-4D0D-9495-CB4C582D6B17Q55176404-F7ED8286-E598-4DBB-8F6D-1F1CB80464CBQ55619193-6B6ADF46-05AB-4D36-A88C-3ABD17A3FA97Q58129718-78D05D35-33E2-41B4-9ABA-264DEFFC2DECQ58419002-5D3ED476-9576-49BC-9DDC-723D4C534874
P2860
Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Xanthine oxidase inhibition fo ...... atic review and meta-analysis.
@en
Xanthine oxidase inhibition fo ...... atic review and meta-analysis.
@nl
type
label
Xanthine oxidase inhibition fo ...... atic review and meta-analysis.
@en
Xanthine oxidase inhibition fo ...... atic review and meta-analysis.
@nl
prefLabel
Xanthine oxidase inhibition fo ...... atic review and meta-analysis.
@en
Xanthine oxidase inhibition fo ...... atic review and meta-analysis.
@nl
P2093
P2860
P1476
Xanthine oxidase inhibition fo ...... atic review and meta-analysis.
@en
P2093
Jesse Dawson
Kate McArthur
Kennedy R Lees
Matthew R Walters
Peter Higgins
Terrence J Quinn
P2860
P304
P356
10.1111/J.1755-5922.2011.00277.X
P577
2011-06-12T00:00:00Z